WHAT WE DO
We use our integrative research process to uncover and leverage the best opportunities in emerging high-growth segments in technology and healthcare for the benefit of the investors and growth companies we serve, as well as our broader society and environment. Integrative research draws heavily on our relationships with companies and unifies naturally divergent perspectives, capabilities, skill sets, and relationships, yielding a deep, comprehensive understanding of each segment's near-term and long-term potential.
Technology / SaaS
Healthcare
Environmental Technology
VENTURE
CAPITAL
First Analysis is a leading venture capital investor, having invested more than $800 million over four decades. Leveraging our integrative research process, we partner with strong teams leading rapid-growth companies to build industry leaders in the targeted sectors where we are acknowledged experts and where success benefits not only our investors, but also our broader society and environment.
INTEGRATIVE
RESEARCH
Integrative research means our extensive company research informs every thesis and perspective. The result is deep industry knowledge, expertise, and trend insights that yield valuable results for our clients and partners.
INVESTMENT
BANKING
Our investment bankers have a wealth of industry knowledge, contacts, and execution expertise to drive strategic transactions with uncompromised loyalty to our clients.
NEWS & INSIGHTS
First Analysis invests in Yunu, a multi-site clinical trials imaging workflow platform
First Analysis, a leading venture capital investor, has made a new investment in Yunu, an eClinical solutions company that accelerates breakthrough therapies by unifying clinical trials imaging data and workflows, both within and across cancer centers. First Analysis was the lead investor in the institutional round that will accelerate further development and commercialization of the Yunu platform in expanding its offerings to pharma sponsors.
September 29, 2022
First Analysis, a leading venture capital investor, has made a new investment in Yunu, an eClinical solutions company that accelerates breakthrough therapies by unifying clinical trials imaging data and workflows, both within and across cancer centers. First Analysis was the lead investor in the institutional round that will accelerate further development and commercialization of the Yunu platform in expanding its offerings to pharma sponsors.
September 29, 2022
First Analysis acted as the exclusive financial advisor to SyTrue in its sale to ClaimLogiq
First Analysis acted as the exclusive financial advisor to SyTrue in its sale to ClaimLogiq, a leading technology enabling payment integrity platform. SyTrue is a pioneer in healthcare natural language processing technology, creating a seamless and cohesive solution for clinical, coding and medical record reviews.
August 16, 2022
First Analysis acted as the exclusive financial advisor to SyTrue in its sale to ClaimLogiq, a leading technology enabling payment integrity platform. SyTrue is a pioneer in healthcare natural language processing technology, creating a seamless and cohesive solution for clinical, coding and medical record reviews.
August 16, 2022
First Analysis invests in DeviceOps software provider EdgeIQ
First Analysis, a leading venture capital investor, has made a new investment in EdgeIQ, provider of an API-first DeviceOps platform. The investment will enable EdgeIQ to accelerate releasing new product capabilities and expand its leadership team and overall global market presence. First Analysis led the $8.5 million round.
July 22, 2022
First Analysis, a leading venture capital investor, has made a new investment in EdgeIQ, provider of an API-first DeviceOps platform. The investment will enable EdgeIQ to accelerate releasing new product capabilities and expand its leadership team and overall global market presence. First Analysis led the $8.5 million round.
July 22, 2022
©2022 by First Analysis Corporation.
One South Wacker Drive
  ·  
Suite 3900
  ·  
Chicago, IL 60606
  ·  
312-258-1400
First Analysis Corp. is the parent of First Analysis Private Equity Management V-B, LLC, an SEC-registered investment adviser that offers venture capital investment advisory services, and First Analysis Securities Corp. (FASC), a registered broker dealer with FINRA and member SIPC that offers investment banking services and securities.